Seattle Genetics, Inc. (SGEN) Initiates Phase 1 Trial of SGN-CD33A in Acute Myeloid Leukemia (AML)
7/15/2013 10:07:13 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (NASDAQ:SGEN) today announced initiation of a phase 1 clinical trial of SGN-CD33A for patients with acute myeloid leukemia (AML). SGN-CD33A is a novel antibody-drug conjugate (ADC) utilizing Seattle Genetics’ newest ADC technology targeted to CD33, which is expressed on most AML cells. The CD33 antibody is attached to a highly potent cytotoxic DNA-crosslinking agent, a pyrrolobenzodiazepine (PBD) dimer, via a proprietary site-specific conjugation technology to a monoclonal antibody with engineered cysteines (EC-mAb). The trial is designed to assess the safety and anti-leukemia activity of SGN-CD33A.
Help employers find you! Check out all the jobs and post your resume.